

NEUPATH HEALTH REPORTS THIRD QUARTER 2024 RESULTS

- **Third quarter total revenue of \$17.6 million, up 9% year-over-year**
- **Adjusted EBITDA⁽¹⁾ of \$0.7 million, up 9% year-over-year, and our 23rd consecutive quarter of positive adjusted EBITDA**
- **Positive cash flow, with net debt down 8% versus September 30, 2023, and with significant investments in our facilities to support future growth**

TORONTO, ONTARIO, November 14, 2024 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and nine months ended September 30, 2024. All figures are in Canadian dollars, unless otherwise noted.

“Continued organic growth and a focus on operations is funding investments in our clinics, which will drive growth in coming years,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “Additionally, our improving Balance Sheet is allowing us to evaluate new opportunities for organic and inorganic growth to better serve more patients, with more services, in more communities.”

Financial and Operational Highlights

- Total revenue was \$17.6 million and \$53.9 million for the three and nine months ended September 30, 2024, up 9% over the prior year three-month and nine-month periods;
- Adjusted EBITDA was \$0.7 million and \$2.9 million for the three and nine months ended September 30, 2024, up 9% over the prior year three-month period and up 20% over the prior year nine-month period;
- For the nine months ended September 30, 2024, capacity utilization improved to 74%, up from 67% for the nine months ended September 30, 2023; and
- As at September 30, 2024, the Company had \$3.1 million in cash and cash equivalents and long-term debt of \$6.0 million, of which \$2.3 million is interest-bearing.

⁽¹⁾ *Non-International Financial Reporting Standard (“IFRS”) and Other Financial Measures defined by the Company below.*

Q3 2024 Financial Results

Total Revenue

Total revenue is comprised of clinic revenue and non-clinic revenue. Total revenue was \$17.6 million and \$53.9 million for the three and nine months ended September 30, 2024 compared to \$16.1 million and \$49.3 million for the three and nine months ended September 30, 2023.

Clinic Revenue

Clinic revenue is generated through the provision of medical services to patients. Clinic revenue was \$16.3 million and \$49.8 million for the three and nine months ended September 30, 2024 compared to \$14.9 million and \$45.7 million for the three and nine months ended September 30, 2023. The increase in clinic revenue for the three and nine months ended September 30, 2024 was primarily due to stronger revenues from fluoroscopy and increased patient volumes from existing medical clinics. Capacity utilization was 73% and 74% in the three and nine months ended September 30, 2024 compared to 65% and 67% for the three and nine months ended September 30, 2023. The improvement in capacity utilization was primarily driven by increased patient volumes and efficiency through continued optimization of clinic space, including the relocation of its Mississauga facility and corporate office space in August 2024, further reducing its clinic footprint.

Non-clinic Revenue

Non-clinic revenue was \$1.2 million and \$4.1 million for the three and nine months ended September 30, 2024 compared to \$1.2 million and \$3.6 million for the three and nine months ended September 30, 2023. Non-clinic revenue is earned from physician staffing allocation services where the Company provides physicians for provincial

and federal correctional institutions across Canada, and from contract research services provided to pharmaceutical companies and clinical research organizations. This revenue fluctuates depending on the need for physicians in certain institutions and the timing and enrolment of clinical studies that the Company is working on.

Gross margin % was 18.3% and 19.0% for the three and nine months ended September 30, 2024 compared to 18.3% and 18.4% for the three and nine months ended September 30, 2023. The increase in gross margin was primarily driven by higher revenues from fluoroscopy and increased patient volumes at existing medical clinics compared to the three and nine months ended September 30, 2023. (see *Non-IFRS Financial Measures - Gross Margin and Gross Margin % below*).

Adjusted EBITDA was \$0.7 million and \$2.9 million for the three and nine months ended September 30, 2024 compared to \$0.7 million and \$2.4 million for the three and nine months ended September 30, 2023.

Liquidity and Capital Resources

As at September 30, 2024, the Company's net debt was \$2.8 million, compared to \$3.1 million as at September 30, 2023. The Company's net debt as at September 30, 2024 consisted of \$3.1 million of cash and cash equivalents and long-term debt of \$6.0 million compared to \$3.0 million of cash and cash equivalents and long-term debt of \$6.1 million as at September 30, 2023.

For more information see Note 6, *Long-Term Debt* in the Company's Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2024, and Note 5, *Long-Term Debt* in the Company's Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2023.

Non-IFRS Financial and Other Measures

The Company discloses non-IFRS measures (such as EBITDA, adjusted EBITDA, and gross margin) and non-IFRS ratios (such as gross margin %) that do not have standardized meanings prescribed by International Financial Reporting Standards ("IFRS"). The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance. Non-IFRS financial measures and other measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other reporting issuers and therefore unlikely to be comparable to similar measures presented by other companies. Furthermore, these non-IFRS measures and other measures should not be considered in isolation or as a substitute for measures of performance or cash flows as prepared in accordance with IFRS. These measures should be considered as supplemental in nature and not as a substitute for related financial information prepared in accordance with IFRS.

EBITDA and Adjusted EBITDA

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA, as EBITDA, excluding stock-based compensation expense, restructuring costs, gain on derecognition of other obligations, fair value adjustments, transaction costs, impairment charges, gain on sale of building, government loan forgiveness and finance income. Management believes EBITDA and adjusted EBITDA are useful supplemental non-GAAP measures to determine the Company's ability to generate cash available for operations, working capital, capital expenditures, debt repayments, interest expense and income taxes.

The following table provides a reconciliation of net and comprehensive income (loss) to EBITDA and adjusted EBITDA:

	Three months ended September 30		Nine months ended September 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Net and comprehensive income (loss)	(323)	356	(305)	177
Add back:				
Depreciation and amortization	575	627	1,709	1,865
Interest cost	242	235	721	661
Income tax expense	52	135	175	259
EBITDA	546	1,353	2,300	2,962
Add back:				
Stock-based compensation	17	47	81	139
Transaction costs	175	40	529	92
Finance income	-	(2)	-	(8)
Gain on sale of building	-	(758)	-	(758)
Adjusted EBITDA	738	680	2,910	2,427
Attributed to:				
Shareholders of NeuPath Health Inc.	640	680	2,672	2,450
Non-controlling interest	98	-	238	(23)
	738	680	2,910	2,427

Gross Margin and Gross Margin %

Management believes gross margin and gross margin % are important supplemental non-GAAP measures for evaluating operating performance and to allow for operating performance comparability from period-to-period. Gross margin is calculated as total revenue minus cost of medical services. Gross margin % is calculated as gross margin divided by total revenue.

The following table provides a reconciliation of total revenue to gross margin:

	Three months ended September 30		Nine months ended September 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Clinic revenue	16,335	14,856	49,769	45,715
Non-clinic revenue	1,217	1,229	4,149	3,579
Total revenue	17,552	16,085	53,918	49,294
Cost of medical services	14,338	13,145	43,687	40,230
Gross margin⁽¹⁾	3,214	2,940	10,231	9,064
Gross margin %⁽¹⁾	18.3%	18.3%	19.0%	18.4%

⁽¹⁾ Gross margin and gross margin % are non-IFRS measures. Please refer to *Non-IFRS Financial Measures* above.

For further details on the results, please refer to NeuPath's Management, Discussion and Analysis and Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2024, which are available on the Company's website (www.neupath.com) and under the Company's profile on SEDAR+ (www.sedarplus.ca).

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to

employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company's expectation of continued operational improvements in 2024 and the execution of the Company's growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company's annual information form dated March 14, 2024 filed on SEDAR+ under the Company's profile at www.sedarplus.ca.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.

For more information, please contact:

Jeff Zygouras
Chief Financial Officer
info@neupath.com
(905) 858-1368

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.